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Abstract
Adeno-associated virus (AAV) vectors have been a powerful gene delivery vehicle to the retina for 
basic research and gene therapy. For many of these applications, achieving cell-type specific 
targeting and high transduction efficiency is desired. Recently, there has been increasing interest in 
AAV-mediated gene targeting to specific retinal bipolar cell types. A 200-bp enhancer in 
combination with a basal SV40 promoter has been commonly used to target transgenes into ON-
type bipolar cells. In the current study, we searched for additional cis-regulatory elements in the 
mGluR6 gene for improving AAV-mediated transduction efficiency into retinal bipolar cells. Our 
results showed that the combination of the endogenous mGluR6 promoter with additional 
enhancers in the introns of the mGluR6 gene markedly enhanced AAV transduction efficiency as 
well as made the targeting more selective for rod bipolar cells in mice. Furthermore, the AAV 
vectors with the improved promoter could target to ON bipolar cells with robust transduction 
efficiency in the para-fovea and the far peripheral retina of marmoset monkeys. The improved 
mGluR6 promoter constructs could provide a valuable tool for genetic manipulation in rod bipolar 
cells in mice and facilitate clinical applications for ON bipolar cell-based gene therapies.
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INTRODUCTION
Adeno-associated virus (AAV) vectors have been a powerful gene delivery vehicle to the 
retina for basic research and gene therapy1-4. For many of these applications, achieving cell-
type specific targeting and high transduction efficiency is desired but challenging5.
Retinal bipolar cells are comprised of multiple types that are classified into rod and cone 
bipolar cells based upon their synaptic inputs and ON- and OFF-types based upon their 
light-response polarity6. In mammals, there are multiple ON- and OFF-types of cone bipolar 
cells and a single ON-type of rod bipolar cells (RBCs). Recently, there has been increasing 
interest in targeted gene expression in specific retinal bipolar cell types, notably for newly 
emerging optogenetic gene therapy for vision restoration7-10.
A well-known promoter for ON bipolar cell targeting is the mGluR6 promoter. A 10 kb 
sequence upstream of the mGluR6 gene has been shown to be sufficient to drive transgene 
expression in ON bipolar cells in transgenic animals14-16. Within the 10 kb sequence, a 200-
bp mGluR6 enhancer, referred to as 200En hereinafter, was identified to be necessary for 
achieving ON bipolar cell targeting14. Most previous studies for ON bipolar cell targeting 
were conducted using the 200En with a basal SV40 promoter8,14,15; however, AAV-
mediated expression with the mGluR6 promoter in retinal bipolar cells is low. Efforts have 
been continuously made to improve AAV-mediated gene delivery and expression efficiency 
to bipolar cells, especially for optogenetic gene therapy15-17. Factors that have been 
suggested to contribute to the low transduction efficiency in bipolar cells include physical 
barrier especially via intravitreal delivery, viral tropism, proteasome-mediated degradation, 
intracellular trafficking, and promoter strength15-20.
Promoters and enhancers are key cis-regulatory elements in the regulation of gene 
expression21-24. In this study, we searched for additional regulatory elements of the mGluR6 
gene for improving the AAV-mediated transduction efficiency in bipolar cells. We found that 
the use of the endogenous mGluR6 promoter and its intron sequences markedly enhanced 
the AAV-mediated transduction efficiency in RBCs in mice. For evaluating its potential 
clinical applications, we also examined the AAV vectors with the optimized promoter 
construct in a non-human primate. We showed that the AAV vectors with the improved 
promoter construct can target to ON bipolar cells with robust expression around the fovea 
and the far peripheral regions of the retina of common marmosets (Callithrix jacchus).
RESULTS
Bioinformatics analysis
To identify additional cis-regulatory elements of the mGluR6 gene, we conducted a 
bioinformatics analysis covering from a 10 kb upstream sequence through a 15 kb intrinsic 
sequence of the mouse mGlur6 gene (Fig. 1a). The previously identified 200-bp mGluR6 
enhancer (200En; yellow box)14 is located closed to the 5′ end of the 10 kb upstream 
sequence. First, a potential mGluR6 promoter sequence of 1095 bp (−1 to −1095; 
nucleotides relative to the translation start site), hereinafter referred to as mGluR1095P, was 
identified (orange arrow box) immediately upstream of the transcriptional start site of the 
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mGluR6 gene. Second, the binding sites for p300, an important transcription co-activator 
that is usually associated with promoter and enhancers24, were marked (red circles). Within 
p300 dense binding regions, the binding sites for major transcription factors were identified 
(pink circles). Most of these transcription factors are located within intron 3, 4 and 6. Third, 
four conserved regions (among mouse, rat, human and dog) were identified (blue boxes or 
lines). The longest one largely overlaps with the 200En. Among the other conserved regions, 
one is located in the proximal region of the mGluR1095P and two are located in the In4.
The use of endogenous mGluR6 promoter
The optimization of the mGluR6 promoter constructs was performed in the mouse retina in 
vivo via intravitreal injection. The intravitreal route was chosen because it has the advantage 
of producing less retinal damage during virus injection procedures and achieving a broad 
homogeneous expression across the whole retina. The virus vectors were made by packaging 
into AAV2 serotype 2 with an Y444F capsid mutation, referred to as AAV2/2-Y444F, which 
has been previously reported to facilitate the transduction of retinal neurons including 
bipolar cells through intravitreal injection19,20,25. Promoter constructs containing the 200En 
and a varied combination of regulatory elements and promoters were evaluated by driving 
the transgene of mCherry (Fig. 1b).
Because the previous studies for targeting ON bipolar cells were conducted by combining 
the 200En with a basal SV40 promoter, 200En-SV408,14,15, we first examined whether the 
AAV-mediated transduction efficiency to ON bipolar cells could be improved by using the 
endogenous mGluR6 promoter. For the purpose of comparison, the AAV2-mediated 
expression with the promoter construct of the 200En-SV40 was tested. Consistent with these 
previous reports, the expression of mCherry was predominantly observed in retinal bipolar 
cells in retinal whole-mounts (Fig. 2a; left and middle panels) and vertical sections (Fig. 2a; 
right panel). At the border between inner plexiform layer (IPL) and ganglion cell layer 
(GCL), many axon terminals of bipolar cells were observed (Fig. 2a, middle panel). 
However, the expression was relatively weak (see Fig. 2g). In addition, weak expression of 
mCherry was frequently observed in some cells located in the inner nuclear layer (INL) and 
GCL after the enhancement of mCherry with antibody (see left panel in Fig. 2a; marked by 
arrows). The latter indicates some off targeting to retinal third order neurons.
In contrast, the transduction efficiency of the AAV vectors using the promoter construct by 
replacing the basal SV40 promoter with mGluR1095P was found to be markedly increased. 
Higher expression of mCherry was observed in retinal bipolar cells as evidenced both in 
retinal whole-mounts and vertical sections (Fig. 2b). The average fluorescence intensity was 
increased by approximately 3.7 times in comparison to the control with the 200En-SV40 
promoter (Fig. 2g).
We next asked if the promoter could be shortened. A short promoter containing the 3′ 500 
bp sequence (−2 to −501), referred to as mGluR500P (see Fig. 1a), was chosen based upon 
the presence of the p300 and a conserved region. The construct with this short promoter, 
200En-mGluR500P, not only worked but also further improved transduction efficiency (Fig. 
2c). The average fluorescence intensity was increased by 87% as compared to that with 
mGluR1095P (see Fig. 2g).
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For both constructs with the mGlu1095P and mGluR500P promoter, the specificity to 
bipolar cells was also improved. Weak expression in other retinal neurons was only 
occasionally observed after the enhancement of mCherry with antibody. Thus, our results 
indicate that the combination of the 200En and the endogenous mGluR6 promoter can 
markedly increase transduction efficiency as well as improve the selectivity to bipolar cells.
Regulatory elements in the introns of mGluR6 gene
Because three introns of the mGluR6 gene contain several important transcription binding 
sites (see Fig. 1a), we next tested whether these introns could regulate the transduction 
efficiency. First, the addition of a 1130 bp sequence (4677 to 5806) of the intron 4 (referred 
to as In4) and a 807 bp sequence (3029 to 3835) of the intron 3 (referred to as In3) to either 
the 200En-mGluR1095P or the 200En-mGluR500P were found to further increase the 
expression level of mCherry in bipolar cells by 69% or 61% in comparison to the 
corresponding constructs without adding introns, respectively (Fig. 2d and e; see Fig. 2g).
Because AAV has a limited packaging capacity of 4.7 kb, we also made efforts to shorten 
the In3 and In4. We found that the combination of a shorten In4, In4s (690 bp; its nucleotide 
sequence is shown in Table S1), with the In3 further increased the average fluorescence 
intensity by 62% (Fig. 2f; also see Fig. 2g). Again, no significant off targeting was observed 
in other retinal neurons including the cells in the GCL. On the other hand, the use of a 
shortened In3, In3s (587 bp; see Table S1), by combining the In4s was found to decrease the 
expression level (data not shown). The addition of a 700 bp sequence (7457 to 8156) of the 
intron 6 (see Fig. 1a) to In4s-In3s-200En-mGluR500P was not found to improve the 
expression (data now shown), thereby suggesting that the In6 does not play a role in the 
regulation of mGluR6 gene expression.
As shown in Figure 2h, the transduced cell densities for the virus vectors with the improved 
promoter constructs were all increased compared to that with 200En-SV40 promoter, 
especially for the virus vectors with the promoter construct of In4s-In3-200En-mGluR500P. 
With the best optimized mGluR6 promoter construct, In4s-In3-200En-mGluR500P, the 
AAV-mediated expression could be achieved across the entire retina as a sample image 
shown in Figure 3a. The highest expression was usually observed in the peripheral regions 
of the retina.
Thus, we optimized two mGluR6 promoter constructs: a short version with 200En-
mGluR500P and a longer version with In4s-In3-200En-mGluR500P. The AAV vectors with 
these two promoter constructs, especially the longer version, markedly increase transduction 
efficiency but maintain specificity to bipolar cells.
The expression was predominately in rod bipolar cells
The use of mGluR6 promoter would be expected to target the transgene to both ON cone 
bipolar cells and RBCs. However, the axon terminals of the mCherry expressing bipolar 
cells with the above optimized mGluR6 promoter constructs appeared to have the 
morphological characteristics of RBCs26; the labeled cells were stratified close to retinal 
ganglion cells with a few large terminal buttons. To confirm whether the targeted bipolar 
cells are RBCs, we performed double immunostaining with antibodies against protein kinase 
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C (PKC), a marker of RBCs, and mCherry26. Indeed, as assessed in retinal whole-mounts, 
98% and 92% of the mCherry-positive bipolar cells were co-labeled with PKC for the 
optimized short and long mGluR6 promoter constructs respectively (Fig. 4a and c; Table 1), 
thereby indicating that the vast majority of them are RBCs. Only a few mCherry-positive 
bipolar cell terminals were observed not to be co-labeled with PKC in retinal vertical 
sections (Fig. 4b and d; pointed by arrows). In the best transduced regions by the virus 
vector with the In4s-In3-200En-mGluR500P promoter, almost all RBCs were transduced 
based upon PKC and mCherry co-labeling (see Fig. 4c). On average, 58% and 86% of RBCs 
were transduced in the peripheral retinas for the short and long mGluR6 promoter 
constructs, respectively (Table 1), under our conditions (with the injection of 1.5 μL virus 
vectors at the titer of 1 × 1013 vg/mL).
To address whether the predominant targeting to RBCs is due to the property of the 
endogenous mGluR6 promoter, we performed co-labeling of PKC and mCherry in the retina 
that was transduced by the virus vectors with the 200En-SV40 promoter. The majority of the 
transduced cells were also RBCs although mCherry-positive but PKC negative bipolar cells 
were frequently observed (Figure S1). Our results thus suggest the virus vectors with the 
200En-SV40 promoter also preferably target RBCs but the virus vectors with the 
endogenous mGluR6 promoter appear to be more selective to RBCs.
Since a new AAV2 capsid variant, named 7m8, developed through in vivo-directed evolution 
in the mouse retina, was recently reported to be able to improve transduction efficiency via 
intravitreal injection both in the mouse and primate retinas27, we therefore also produced the 
virus vector for the promoter construct of In4s-In3-200En-mGluR500P with the 7m8 capsid 
plus Y444F mutation, referred to as AAV2.7m8-Y444F hereinafter. Its expression was first 
examined in the mouse retina. Consistently, the overall expression was improved as 
evidenced by the increase of the mCherry-positive bipolar cells in retinal whole-mounts 
(Fig. 3b and 5a). Quantitatively, a higher percentage of PKC-positive cells (96%) was co-
labeled with mCherry (Table 1). However, the percentage (86%) of PKC and mCherry co-
labeled cells in the mCherry-positive bipolar cells was decreased comparing to that of the 
virus vector with the AAV2/2-Y444F capsid, suggesting that other bipolar cells other than 
RBCs were transduced. Indeed, in retinal vertical sections, more PKC-negative and 
mCherry-positive bipolar cells were observed (Fig. 5b-d). Most of these PKC-negative 
bipolar cells were co-labeled with antibody against Gγ13, a marker of both ON cone bipolar 
cells and RBCs28 (Fig. 5e-g; pointed by arrows in Fig. 5g), indicating that they are mainly 
ON cone bipolar cells. Additionally, more weakly transduced RGCs or amacrine cells were 
observed (pointed by arrow heads in Fig. 5g). Together, these results indicate that the virus 
vector with the AAV2.7m8-Y444F capsid improves the transduction efficiency but is slightly 
less selective to RBCs compared to that of the virus vector with the AAV2/2-Y444F capsid 
in the mouse retina.
AAV-mediated expression in the marmoset retina
To begin evaluating its potential clinical applications, we examined the AAV-mediated 
specificity and transduction efficiency in the marmoset retina using virus vectors with the 
In4s-In3-200En-mGluR500P promoter packaged by both AAV2/2-Y444 and AAV2.7m8-
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Y444F capsids. The virus vectors were administered via intravitreal injection in four eyes of 
four animals, three eyes were injected with the AAV2/2-Y444F capsid and one eye was 
injected with the AAV2.7m8-Y444F capsid. As shown in Fig. 6a and b, for both virus 
vectors, the expression of mCherry was observed in the regions surrounding the fovea 
(labeled as 1; also pointed by arrows), the far peripheral retinas (labeled as 2) first occurring 
~5 – 6 mm away from the fovea, and along retinal blood vessels (labeled as 3; the insertions 
show the high magnification for the labeled areas). The expression was more robust with the 
vectors carrying the AAV2.7m8-Y444F capsid (also see Table 2). At a higher magnification, 
the mCherry-positive cells with the morphological appearance of bipolar cells formed a 
dense ring surrounding the center of the fovea (Fig. 6c and d). The highest transduction 
efficiency was observed in the far peripheral regions of the retina.
To determine the transduced bipolar cell types, we performed triple immunolabeling in 
retinal whole-mounts in the peripheral retina of 6 – 8 mm away from the fovea with 
antibodies against mCherry, PKC, and Gγ13. For the virus vector with the AAV2.7m8-
Y444F capsid, 95% of the mCherry-positive bipolar cells were co-labeled with Gγ13 (Fig. 
7a-c; Table 2), indicating that the vast majority of the transduced bipolar cells were ON 
bipolar cells. PKC co-labeling indicated that only 17% of the transduced bipolar cells were 
RBCs (Fig. 7d-f; Table 2). Based upon the co-labeling of PKC and Gγ13 in the examined 
regions, 24 – 25% of the ON bipolar cells were RBCs (see Table 2), consistent with the 
previously reports that only a small portion of the ON bipolar cells is RBCs in the marmoset 
retina29,30. The vast majority (93%) of the Gγ13-positive cells (ON bipolar cells), and the 
majority (72%) of the PKC-positive cells (RBCs) were transduced (see Table 2). Together, 
these results indicate that in the peripheral marmoset retina the virus vector with 
AAV2.7m8-Y444F capsid can efficiently target the majority of the ON cone bipolar cells 
and RBCs with high transduction efficiency. This was also confirmed by double-labeling of 
mCherry with Gγ13 or PKC in retinal vertical sections. The mCherry-positive cells were 
almost all co-labeled with Gγ13 (Fig. 8a). mCherry-positive, but Gγ13-negative bipolar cells 
were only occasionally observed. Additionally, the vast majority of Gγ13-positive and the 
majority of PKC-positive cells were co-labeled with mCherry (Fig. 8a and b).
For the virus vector with AAV2/2-Y444F capsid, the specificity is similar to that of the virus 
vector with AAV2.7m8-Y444F capsid (Figure S2). That is, the virus vectors were observed 
to predominantly target both ON cone bipolar cells and RBCs, however the overall 
transduction efficiency is reduced (Table 2).
Discussion
In this study, we have improved the mGluR6 promoter constructs for AAV-mediated retinal 
bipolar cell targeting via intravitreal administration in the mouse retina. The AAV vectors 
with the best optimal promoter construct, In4s-In3-200En-mGluR500P, increased the 
expression level by over 20x in comparison to that of the 200En-SV40 promoter. The 
maximal genome that could be packaged into AAV vectors is ~4.7 kb31. The In4s-
In3-200En-mGluR500P construct is approximately 2.2 kb in length; so for AAV-mediated 
expression, it can still hold a transgene of up to 2.0 kb, assuming the use of a 0.5 kb poly(A) 
sequence. For longer transgenes, the short version of the mGluR6 promoter construct, 
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200En-mGluR500P, could be used, which can hold a transgene of up to 3.5 kb. In addition, 
the optimized promoter construct also reduced off-targeting to other retinal neurons.
The increase in the transduction efficiency was achieved by using the endogenous mGluR6 
promoter and by incorporating the mGluR6 gene introns. Our results indicate that the 
endogenous mGluR6 promoter is more effective than the basal SV40 promoter. In addition, 
our results indicate the presence of the additional enhancers in the introns of 3 and 4 of 
mGluR6 gene. Interestingly, the shortened mGluR6 promoter and the shortened In4 were 
found to be more effective than the long versions. The latter suggests the presence of 
suppressors in these sequences23. It may be possible to further improve the transduction 
efficiency by fine-tuning these sequences or by searching for additional regulatory elements.
Our results show that the use of endogenous mGluR6 promoter also results in the 
improvement of the selectivity to bipolar cells. This is important because an increase of the 
transduction efficiency is usually associated with an increase in off-targeting. Interestingly, 
in the mouse retina, the promoter constructs with the endogenous mGluR6 promoter were 
found to predominantly target to RBCs. Our results indicate that the 200En-SV40 construct 
also preferably targeted to RBCs, suggesting that this property is in part due to the property 
of the 200En. However, the use of the endogenous mGluR6 promoter appeared to make the 
virus vectors more selective to RBCs. Because the 10 kb sequence upstream to the 
translation start site was shown to be capable of targeting to all ON bipolar cells11-13, it is 
possible that there is additional regulatory element(s) within the 10 kb sequence that may 
regulate the transgene expression in ON cone bipolar cells. Further studies would be 
interesting to search such regulatory elements.
It should be noted that in addition to the commonly used 200En-SV40 promoter, an 
enhanced mGluR6-based promoter containing multiple 200Ens, 4 × 200En, was used to 
improve the transduction efficiency to ON bipolar cells in the mouse retina16. A bipolar cell 
selective MiniPromoter was also reported to target ON bipolar cells in the mouse retina32,33. 
However, since different AAV capsids and variants were used in these studies, a comparison 
side-by-side would be required to determine the selectivity and transduction efficiency of the 
constructs developed in this study over these previously reported promoters.
Nevertheless, the predominant selectivity of our improved constructs for RBCs will offer a 
valuable tool for genetic manipulation in RBCs in the mouse model. Due to the low 
transduction efficiency and the lack of high selectivity of virus mediated delivery in general, 
cell-type specific targeted genetic manipulation was commonly achieved by using transgenic 
lines, especially Cre lines. However, creating transgenic mouse lines is both costly and time 
consuming. In fact, no highly RBC-selective Cre mouse lines are currently available20. Thus, 
with the improved targeting selectivity and transduction efficient for RBCs, the AAV-
mediated gene delivery would be a more feasible and cost efficient approach for introducing 
Cre or transgenes directly in RBCs in the mouse retina. This approach would be particularly 
advantageous for cell targeting in species in which the transgenic strategy is not applicable.
Our results show that the AAV vectors with the optimized promoter construct can selectively 
target bipolar cells in the marmoset retina with intravitreal injection. Robust transduction 
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efficiency can be achieved in the regions surrounding the fovea and in the far peripheral 
retina. The vast majority of the ON bipolar cells in the far peripheral retina could be 
transduced, indicating the promoter construct is highly effective in the primate.
Interestingly, in contrast to the results observed in the mouse retina, the AAV vectors with 
the optimized mGluR6 promoter construct in the marmoset retina were found to transduce 
not only RBCs but also ON cone bipolar cells. This species difference could not be 
explained by the difference in the ratios of RBCs versus ON cone bipolar cells between 
these two species. In the mouse retina, the majority of the transduced bipolar cells (92% and 
82% for the virus vectors with AAV2/2-Y444F and AAV2/7m8-Y444F capsid, respectively; 
Table 1) are RBCs. The ratio of RBCs and ON cone bipolar cells was reported to be 
~1.3:134. The density of our counted RBCs (10,000 – 11,000/mm2; see Table 1) is close to 
the low end of the previously reported range (11,000 – 15,000/mm2)34,35. In contrast, in the 
marmoset retina, only 17 – 18% of the transduced bipolar cells are RBCs. The ratio of RBCs 
and ON cone bipolar cells based on our counting is about 1:4 in the examined far peripheral 
region (6 – 8 mm away from the fovea) (see Table 2). As a note, this ratio appears to be 
higher than that previously reported (1 or 3 mm away from the fovea)29,30, which could be 
overestimated under our conditions, possibly due to the weak labeling of some types of ON 
bipolar cells with Gγ13. The latter may suggest that there is no preferable transduction in 
RBCs in the marmoset retina. Together, our results clearly indicate that the virus vectors 
predominately target RBCs in the mouse retina but target both RBCs and ON cone bipolar 
cells in the marmoset retina.
The difference in targeting between mice and marmosets could be due to a different 
transcriptional regulation between these two species. Further studies of the differences in the 
transcription binding sites between the mouse and marmoset could be performed to 
determine the regulatory components for RBCs and ON cone bipolar cells. Nevertheless, the 
ability of the optimized mGluR6 promoter construct to target all ON bipolar cells by AAV 
vectors offers an effective promoter for ON bipolar cell targeting in the marmosets.
To our knowledge, this study is the first to demonstrate the ability of AAV-mediated 
expression of targeting retinal bipolar cells in non-human primates. The marmoset has 
become increasing popular as a non-human primate model for gene therapy36-39 and eye and 
vision research because the anatomical properties of the marmoset eye and retina are similar 
to those of humans40-44. Thus, the improved mGluR6 promoter constructs developed in this 
study could facilitate pre-clinical testing and applications for the ON bipolar cell-based gene 
therapies, especially optogenetic gene therapy for vision restoration9,10, 45-47.
Our results showed that the transduction efficiency in the marmoset retinas was varied in 
different retinal regions. The transduction efficiency was very low or none beyond the 
regions of the para-fovea and the far peripheral retina, excepting around blood vessels. A 
similar expression pattern was previously reported by AAV vectors with strong ubiquitous 
promoters, e.g., CAG and CMV, which non-selectively transduced inner retinal neuron in the 
marmoset38 and the macaque retina27,48. Such uneven transduction efficiency may be due to 
the presence of certain retinal barriers, mainly the inner limiting membrane18,38.
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Our results also showed that AAV vectors that use AAV2.7m8 capsid variant resulted in a 
marked increase in the overall expression both in mice and marmosets. An increase of 
transduction efficiency in bipolar cells in mice using the AAV2.7m8 capsid was recently 
reported using the 200En-SV40 promoter17. This was proposed to be due to improvement of 
the overall virus penetration in the retina27. Thus further improving the virus penetration in 
the primate retinas is needed. This could be achieved by the combination of optimizing 
capsid variants, enzymatic treatments, or surgery to remove the inner limiting membrane to 
facilitate the virus penetration in the primate retina18,48. Further improvement of the 
transduction efficiency in primates could also be achieved by including additional capsid 
mutations to reduce proteasome-mediated degradation49,50.
MATERIALS AND METHODS
Bioimformatics analysis
Using Ensembl genome browser (www.ensembl.org), mouse mGlurR6 (Grm6) gene 
sequence of 25 kb was downloaded from the National Institutes of Health (NIH) gene 
database (GenBank accession number NC_000077.6). Cis-RED (Nucleic Acid Research; 
http://www.cisred.org/) and Promoter Scan (http://www-bimas.cit.nih.gov/molbio/proscan/) 
programs were used to define the proximal promoter of mGluR6. The transcriptional 
binding site analysis program (TFSEARCH; Parallel Application TRC Laboratory, RWCP, 
Japan) and the Ensembl genome browser (www.ensembl.org) were used to mark the p300 
binding site, an important transcription co-activator, and search specific transcriptional 
factor binding sites. For selection of potential regulatory elements, preference was given to 
conserved DNA sequences and the region with dense p300 binding sites.
Virus vector constructs and virus vectors
A series of AAV2 expression cassettes were constructed to contain the 200En and a variety 
of the combinations of potential regulatory elements and promoters of the mGluR6 gene to 
drive the transgene of mCherry. The DNAs of the mGluR6 regulatory sequences were 
synthesized (Genescript, Piscataway, NJ, USA). All virus vectors in the mouse experiments 
were made by packaging into serotype 2 with an Y444F capsid mutation. The virus vectors 
for the marmoset experiments were also made by packaging into AAV2.7m8 capsid 
construct with the addition of the Y444F capsid mutation. The AAV2.7m8 capsid construct 
was kindly provided by John Flannery at UC Berkeley. The Y444F capsid mutation was 
introduced by site-directed mutagenesis (Agilent Technologies, Santa Clara, CA, USA). 
Viral vectors were packaged and affinity purified by Virovek (Hayward, CA, USA).
Animals and virus injection
C57BL/6J mice of either sex were purchased from Jackson Laboratory (Bar Harbor, ME, 
USA). The marmosets were bred and housed at the State University of New York (SUNY) 
College of Optometry. The mouse-related experiments and procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at Wayne State University and the 
marmoset-related experiments and procedures were approved by the IACUC at SUNY 
College of Optometry. All animal use in this study was in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals.
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Virus injections were performed in mice at the age of about one month. The mouse was 
anesthetized by intraperitoneal injection of a mixture of 120 mg/kg ketamine and 15 mg/kg 
xylazine. Under a dissecting microscope, a small perforation was made in the temporal 
sclera region with a sharp needle. A total of 1.5 μL of viral vectors suspension in saline at a 
concentration of ~1 × 1013 vg/mL was injected into the intravitreal space through the 
perforation with 32-gauge blunt Hamilton syringe. The expression was examined about one 
month after the viral injection.
Virus injections were performed in four juvenile female marmosets at the age of 6 - 9 
months. The animals were anesthetized by intramuscular injection of alfaxalone (2 mg/100 g 
body weight). A total of 30 μL of virus vectors suspension in saline at a concentration of ~1 
× 1013 vg/mL was injected into the intravitreal space with a 0.5-mL syringe with a 32-gauge 
sharp-point needle. The injection site was chosen on the temporal side of the eyeball, 2 mm 
posterior to the limbus. The animals were given an analgesic NSAID (carprofen, 5–10 
mg/kg SC) after surgery. The expression was examined one to two months after the viral 
injection.
Immunohistochemistry
Mice were euthanized by CO2 asphyxiation followed by decapitation. Marmosets were 
anesthetized with alfaxalone (2 mg/100 g body weight) and euthanatized by an intracardiac 
injection of pentobarbital. The retinas were fixed in 4% paraformaldehyde in phosphate 
buffer (PB) for 20 minutes.
In the mouse retina, for quantitative comparison of the expression level of mCherry, the 
fluorescence images were directly taken from the fixed retinas without immunostaining. The 
fixed retinas were dissected in PB solution, flat mounted on slides, and coverslipped after 
adding with mounting medium.
For immunostaining of whole-mount retinas, the retinas were incubated for 2 hrs in a block 
solution containing 5% ChemiBLOCK (Millipore Corp., Bedford, MA, USA), 0.5% Triton 
X-100 and 0.05% sodium azide (Sigma-Aldrich, St. Louis, MO, USA). The primary 
antibodies were diluted in the same solution and applied for two days for mouse retinas and 
seven days for marmoset retinas at room temperature (RT). The retinas were then washed 
several times, followed by incubation in the secondary antibodies for one day for mouse 
retina and five days for marmoset retinas in RT.
For immunostaining of retinal vertical sections, the retinas were cryoprotected in graded 
sucrose (10%, 20%, and 30% wt/vol, respectively, in PB) and cut at 20 μm. The retinal 
sections were incubated for 1 hr in the block solution. The primary antibodies were diluted 
in the same solution and applied overnight in RT, followed by incubation of 2 hrs in the 
secondary antibodies. The secondary antibodies were conjugated to Alexa 594 (1:1000), or 
Alexa 555 (1:1000), or Alexa 488 (1:600; Thermo Fisher Scientific, Waltham, MA, USA), 
or AMCA (1:200; JacksonImmunoResearch, West Grove, PA, USA). The following primary 
antibodies were used in this study: rabbit anti-mCherry (1:500; Clontech, Mountain View, 
CA, USA); goat anti-mCherry (1:2000; Biorbyt, Cambridge, UK); rabbit anti-PKC 
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(1:20,000; Cell Signal, Danvers, MA, USA), mouse anti-PKC (1:10000; Santa Cruz, Dallas, 
Texas, USA), rabbit anti-Gγ13 (1:1000; Santa Cruz).
All images were acquired using a Zeiss Axio Imager 2 microscope with an Apotome 2 
oscillating grating to reduce out-of-focus stray light (Apotome; Carl Zeiss Microscopy 
GmbH, Jena, Germany). Image projections were constructed by collapsing individual z-
stacks of optical sections onto a single plane in ZEN software (Carl Zeiss). The brightness 
and the contrast were adjusted using Adobe Photoshop (Photoshop CS4; Adobe Systems, 
San Jose, CA).
Quantitative fluorescence and cell density measurements
All quantifications for fluorescent intensity and cell density were performed using ImageJ 
software (NIH). In mice, each virus construct was injected in both eyes of 4 – 6 animals. 
Good transgene expression that exhibited relatively even expression across the retina could 
be achieved in about half of the injected eyes. Therefore, randomization or blinding methods 
were not used for comparison. Instead, the best transduced retinas (2 – 3 retinas for each 
construct) were chosen for the analysis. The images were taken from whole-mounts without 
antibody enhancement. In each retina, 6 - 12 images were taken from the peripheral regions 
(~2 mm from the optic disc) with the same fixed exposure time. The fluorescence intensity 
was calculated based upon a method previously described47. The “Image – Adjust – 
Threshold” function of the software was used to select the cells. The “Analyze – Analyze 
particles” function was used to obtain the cell number and the total fluorescence intensity of 
each cell (the sum of the fluorescence values of all pixels within a cell). The average 
fluorescence intensity for each cell was calculated with the following formula: total intensity 
of the cell/the area of the cell - background signal, where background signal = average signal 
for a region without cells. Overlapped cells could be counted as a single cell by the software, 
so all sections were inspected and cell counts were corrected manually. The fluorescence 
intensity was presented as the mean ± SD of the average fluorescence intensity of all 
measured cells. In marmosets, the double and triple immunostaining and cell counting were 
performed in the periphery retina 6 – 8 mm away from the fovea.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Bioinformatics analysis of mGluR6 gene and AAV virus cassette
(a) A schematic diagram of the 25 kb sequence associated with the mGluR6 gene with the 
10 kb upstream sequence of a translation start site (green arrow) and the 15 kb intrinsic 
sequence. The two white boxes preceding the translation start site are non-coding sequence 
(5′ UTR). The ATG (nucleotide 1 – 3) containing an exon was assigned as exon 1 followed 
by other axons (black boxes). The p300 binding sites and the potential important 
transcriptional binding sits are marked as red and pink circles, respectively. Blue squares and 
lines are conserved regions. The 1095 bp and 500 bp mGluR6 promoters are shown as 
orange arrows. The sequences of the intron 3, 4 and 6 (In3, In4, and In6) are shown as green 
boxes. The previous identified 200 enhancer (200En) is shown as a yellow box. The poly(A) 
sites (purple circles) within the 3′ untranslated region (3’UTR; while box) are labeled. 
Three previously reported transcriptional binding sites within the 200En are labeled as blue 
circles14. (b) The schematic diagram of AAV cassettes which contain 200En with or without 
preceding intron(s) and followed by a promoter to drive the transgene of mCherry with a 
human growth hormone poly(A).
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Figure 2. Comparison of the AAV-mediated transduction efficiency in the mouse retinas with 
different mGluR6 promoter constructs
(a – f) The left and middle panels show the whole-mount fluorescence images acquired with 
the focal plan at the inner nuclear layer (left panels) and ganglion cell layer (middle panels) 
without immunolabeling. The right panels show the vertical section images after 
immunolabeling with mCherry. The arrows point to mCherry-expressing ganglion cells or 
amacrine cells. (g) Comparison of the fluorescence intensities of the mCherry-expressing 
bipolar cells with different mGluR6 promoter constructs. (h) Comparison of the cell 
densities of the mCherry-expressing bipolar cells with different mGluR6 promoter 
constructs. The cell density counts were restricted to cells in the inner nuclear layer. The 
data are shown as the mean ± SD. The asterisk indicates statistically significant differences 
at p < 0.05 (one-way ANOVA). OPL: outer plexiform layer; INL: inner nuclear layer; IPL: 
inner plexiform layer; GCL: ganglion cell layer.
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Figure 3. AAV-mediated expression of mCherry in retinal whole mounts in mice
The images of the retina whole-mount injected with the virus vector carrying the promoter 
In4s-In3-200En-mGluR500P with AAV2/2-Y444F (a) and AAV2.7m8-Y444F (b) capsid 
variants.
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Figure 4. Immunostaining for the characterization of mCherry-expressing bipolar cells 
transduced by the virus vectors with AAV2/2-Y444F capsid variant in mice
The expression of mCherry was driven by the promoter construct of 200E-mGluR500P (a, 
b) and In4s-In3-200En-mGluR500P (c, d). Retinal whole-mount (a, c) and vertical section 
(b, d) were co-labeled for mCherry (red; left panels) and PKC, a rod bipolar cell marker 
(green; middle panels). The merged images are shown in the right panels. Arrows point to 
the mCherry positive and PKC negative axon terminals (b, d).
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Figure 5. Immunostaining for the characterization of mCherry-expressing bipolar cells 
transduced by the virus vector with AAV2.7m8-Y444F capsid variant in mice
The expression of mCherry was driven by the promoter construct of In4s-In3-200En-
mGluR500P. (a) Retinal whole-mount were co-labeled for mCherry (red; left panels) and 
PKC (green; middle panels). The merged images are shown in the right panels. (b – g) Triple 
immunolabeling in vertical sections with antibodies against mCherry (b), PKC (c), and Gγ13 
(e). The merged images for mCherry/PKC (d), mCherry/Gγ13 (f), and mCherry/Gγ13/PKC 
(g) are shown. Arrows point to the mCherry positive, PKC negative, but Gγ13-positive axon 
terminals. Arrow heads indicate to the weakly mCherry labeled RGCs and/or amacrine cells.
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Figure 6. AAV-mediated expression patterns in the marmoset retina
The whole-mount retinas show the mCherry expression with AAV vectors driving by In4s-
In3-200En-mGluR500P promoter construct with AAV2/2-Y444F mutation (a) and 
AAV2.7m8-Y444F (b) capsid variant, respectively. The three insertions on the right are the 
magnified images: (1) the fovea as indicated by arrows; (2) the representative regions of the 
far periphery as enclosed by dashed squares; (3) the representative regions containing blood 
vessels. (c, d) The higher magnification images of the fovea.
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Figure 7. Immunostaining for the characterization of mCherry-expressing bipolar cells in the 
retinal whole-mounts of the marmoset with the virus vector carrying AAV2.7m8-Y444F capsid 
variant
Triple immunolabeling with antibodies against mCherry (a), Gγ13 (b), and PKC (d). The 
merged images for mCherry/Gγ13 (c), mCherry/PKC (e), and mCherry/Gγ13/PKC (f) are 
shown. Inset in the upper right corner shows magnification of boxed area. The region is from 
the far periphery (6 – 8 mm from the fovea) of the retina.
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Figure 8. Immunostaining for the characterization of mCherry-expressing bipolar cells in the 
retinal vertical sections of the marmoset
(a) Double immunolabeling with antibodies against mCherry and Gγ13. (b) Double 
immunolabeling with antibodies against mCherry and PKC. The merged images are shown 
in the right panels. The region is from the far periphery (6 – 8 mm from the fovea) of the 
retina transduced with the virus vector carrying AAV2.7m8-Y444F capsid variant.
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Table 1
Comparison of the transduction efficiency and selectivity of virus vectors in the mouse retina.
Virus vector
capsid
Promoter
construct
mCherry(+)
BC
number/mm2
PKC(+) BC
number/mm2
% of mCherry(+)-
PKC(+)/mCherry(
+)
% of
mCherry(+)-
PKC(+)/PKC(+)
number
of
retinas
AAV2/2-
Y444F
200En-
mGluR500P
5916 ± 985 10400 ± 685 98 ± 21 58 ± 12 4
AAV2/2-
Y444F
In4s-In3-
200En-
mGluR500P
8952 ± 1085 10034 ± 505 92 ± 11 86 ± 7.0 3
AAV2.7m8-
Y444F
In4s-In3-
200En-
mGluR500P
12426 ± 964 11096 ± 995 86 ± 9.0 96 ± 1.0 4
The data are presented as the mean ± SD.
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Table 2
Comparison of the transduction efficiency and selectivity of virus vectors in the marmoset retina.
Virus
vector
capsid
Promoter
Construct
mCherry(
+) BC
number/
mm2
Gγ13(+)
BC
number/
mm2
PKC(+)
BC
number/
mm2
% of
mCherry(+)-
Gγ13(+)/mCh
erry(+)
% of
mCherry(+)-
PKC(+)/mChe
rry(+)
% of
mCherry(+)-
Gγ13(+)/ Gγ13(+)
% of
mCherry(+)-
PKC(+)/PKC(+)
number
of
retinas
AAV2/2-
Y444F
In4s-In3-
200En-
mGluR50
0P
4340 ±
383
6137 ±
769
1567 ±
286
86 ± 3.4 18 ± 2.4 78 ± 9.3 50 ± 7.3 1
AAV2.7m
8-Y444F
In4s-In3-
200En-
mGluR50
0P
5992 ±
856
6026 ±
588
1455 ±
101
95 ± 4.2 17 ± 3.1 93 ± 1.9 72 ± 5.6 1
The data are presented as the mean ± SD.
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